Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | JNJ-1802 - (DENV-1 and -2) | Dengue | Phase 2 | Oral | N/A | |
| Johnson & Johnson | ADX71149 (mGlu2 PAM) - (JNJ-40411813) | Epilepsy | Phase 2 | Trial Discontinued | oral | Neurology |
| Johnson & Johnson | ARX788 - (I-SPY 2.2) | HER2-positive breast cancer in the neoadjuvant setting | Phase 2 | Intravenous | Oncology | |
| Johnson & Johnson | Seltorexant (MIN-202) | Major Depressive Disorder | Phase 2 | Trial Completed | Oral | Psychiatric |
| Johnson & Johnson | PN-235 (JNJ-77242113) | Inflammatory bowel diseases (IBD) | Phase 2 | Trial Planned | oral | Gastroenterology |
| Jounce Therapeutics Inc. | Vopratelimab and YERVOY (ipilimumab) - (EMERGE) | Non-small cell lung cancer and bladder cancer | Phase 2 | Intravenous | Oncology | |
| Jounce Therapeutics Inc. | Vopratelimab and JTX-4014 - (SELECT) | Second-line non-small cell lung cancer (NSCLC) patients | Phase 2 | Intravenous | Oncology | |
| Journey Medical Corporation | Emrosi (DFD-29) - (MVOR-1) | Papulopustular rosacea | Phase 3 | Data Released | Oral | N/A |
